Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) – Expanded indication
June 19, 2019 - The FDA approved Gilead’s Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.
Top